Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
NCT03533582Phase 3Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- May 2018
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Targeted Liposomes
- Countries
- 6
01
Overview
A Phase 3 trial of Cisplatin micelle injection (HA132), pegylated liposomal doxorubicin, fluorouracil, vincristine sulfate liposome injection, carboplatin in hepatoblastoma, hepatocellular carcinoma (HCC), sponsored by Children's Oncology Group. Started May 2018; status: active, not recruiting.
02
Drugs
Cisplatin micelle injection (HA132)pegylated liposomal doxorubicinfluorouracilvincristine sulfate liposome injectioncarboplatin
03
Conditions
hepatoblastomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03533582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03533582.